Theranostics 2023; 13(9):3021-3040. doi:10.7150/thno.81826 This issue Cite

Research Paper

Decreased miR-451a in cerebrospinal fluid, a marker for both cognitive impairment and depressive symptoms in Alzheimer's disease

Hu Feng1,2, Panpan Hu1,3, Yan Chen1,2, Huaiqing Sun1,4, Jiachen Cai1,2, Xiaoxin He1,2, Qiuchen Cao1, Mengmei Yin1,4, Yanli Zhang1,2, Qian Li1,2, Junying Gao1,2, Charles Marshall5, Chengyu Sheng1,2, Jingping Shi2,6✉, Ming Xiao1,2✉

1. Jiangsu Key Laboratory of Neurodegeneration, Nanjing Medical University, Nanjing, 211166, China.
2. Brain Institute, Nanjing Brain Hospital, Nanjing Medical University, Nanjing, 210029, China.
3. Department of Anesthetic Pharmacology, Faculty of Anesthesiology, Naval Medical University, Shanghai, 200082, China.
4. Department of Neurology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China.
5. Alice Lloyd College, Pippa Passes, KY, USA.
6. Department of Neurology, the Affiliated Nanjing Brain Hospital of Nanjing Medical University, Nanjing, 210029, China.

Citation:
Feng H, Hu P, Chen Y, Sun H, Cai J, He X, Cao Q, Yin M, Zhang Y, Li Q, Gao J, Marshall C, Sheng C, Shi J, Xiao M. Decreased miR-451a in cerebrospinal fluid, a marker for both cognitive impairment and depressive symptoms in Alzheimer's disease. Theranostics 2023; 13(9):3021-3040. doi:10.7150/thno.81826. https://www.thno.org/v13p3021.htm
Other styles

File import instruction

Abstract

Graphic abstract

Background: Alzheimer's disease (AD) patients are often accompanied by depressive symptoms, but its underlying mechanism remains unclear. The present study aimed to explore the potential role of microRNAs in the comorbidity of AD and depression.

Methods: The miRNAs associated with AD and depression were screened from databases and literature and then confirmed in the cerebrospinal fluid (CSF) of AD patients and different ages of transgenic APP/PS1 mice. AAV9-miR-451a-GFP was injected into the medial prefrontal cortex (mPFC) of APP/PS1 mice at seven months, and four weeks later, a series of behavioral and pathological analyses were performed.

Results: AD patients had low CSF levels of miR-451a, which was positively correlated with the cognitive assessment score, but negatively with their depression scale. In the mPFC of APP/PS1 transgenic mice, the miR-451a levels also decreased significantly in the neurons and microglia. Specific virus vector-induced overexpression of miR-451a in the mPFC of APP/PS1 mice ameliorated AD-related behavior deficits and pathologies, including long-term memory defects, depression-like phenotype, β-amyloid load, and neuroinflammation. Mechanistically, miR-451a decreased the expression of neuronal β-secretase 1 of neurons through inhibiting Toll-like receptor 4/Inhibitor of kappa B Kinase β/ Nuclear factor kappa-B signaling pathway and microglial activation by inhibiting activation of NOD-like receptor protein 3, respectively.

Conclusion: This finding highlighted miR-451a as a potential target for diagnosing and treating AD, especially for those with coexisting symptoms of depression.

Keywords: Alzheimer's disease, miR-451a, BACE1, depression, medial prefrontal cortex


Citation styles

APA
Feng, H., Hu, P., Chen, Y., Sun, H., Cai, J., He, X., Cao, Q., Yin, M., Zhang, Y., Li, Q., Gao, J., Marshall, C., Sheng, C., Shi, J., Xiao, M. (2023). Decreased miR-451a in cerebrospinal fluid, a marker for both cognitive impairment and depressive symptoms in Alzheimer's disease. Theranostics, 13(9), 3021-3040. https://doi.org/10.7150/thno.81826.

ACS
Feng, H.; Hu, P.; Chen, Y.; Sun, H.; Cai, J.; He, X.; Cao, Q.; Yin, M.; Zhang, Y.; Li, Q.; Gao, J.; Marshall, C.; Sheng, C.; Shi, J.; Xiao, M. Decreased miR-451a in cerebrospinal fluid, a marker for both cognitive impairment and depressive symptoms in Alzheimer's disease. Theranostics 2023, 13 (9), 3021-3040. DOI: 10.7150/thno.81826.

NLM
Feng H, Hu P, Chen Y, Sun H, Cai J, He X, Cao Q, Yin M, Zhang Y, Li Q, Gao J, Marshall C, Sheng C, Shi J, Xiao M. Decreased miR-451a in cerebrospinal fluid, a marker for both cognitive impairment and depressive symptoms in Alzheimer's disease. Theranostics 2023; 13(9):3021-3040. doi:10.7150/thno.81826. https://www.thno.org/v13p3021.htm

CSE
Feng H, Hu P, Chen Y, Sun H, Cai J, He X, Cao Q, Yin M, Zhang Y, Li Q, Gao J, Marshall C, Sheng C, Shi J, Xiao M. 2023. Decreased miR-451a in cerebrospinal fluid, a marker for both cognitive impairment and depressive symptoms in Alzheimer's disease. Theranostics. 13(9):3021-3040.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image